Executives
Moon Sue Lee
Chief Executive Officer
CEO, GluGene Therapeutics
Co-founder, GluGene Therapeutics (Serial Entrepreneur)
Founder, InnoTherapy Inc. (KOSDAQ IPO)
Minister’s Award, Ministry of SMEs and Startups
Global Regulatory Affairs/Clinical Development/GMP Operations/Pricing Strategy
Ph.D., M.S., B.S. in Biological Sciences, KAIST
SAIT (Samsung Advanced Institute of Technology), Strategic Planning
CJ Pharma, Strategic Planning
Jae-Hyung Jang
Chief Technology Officer
Chief Technology Officer, GluGene Therapeutics
Co-founder, GluGene Therapeutics (Professor-initiated Startup)
Professor, Department of Chemical and Biomolecular Engineering, Yonsei University
Global Expert in AAV Capsid Engineering
20+ Years of AAV Gene Delivery Vector Development Research
AAV Publications (109+) / Patents (47+) / Technology Transfers (4+)
Postdoctoral Researcher, UC Berkeley (Schaffer Lab)
Ph.D. in Department of Chemical and Biological Engineering, Northwestern University
B.S. in Chemical Engineering, Yonsei University
Chang-Yeon Kim
VP | Global Business Development/Strategy
Head of Business Development, GluGene Therapeutics
US FDA and EU Approvals for Hemostatic Agents
US and International Clinical Development, Commercialization
Chung-Ang University Department of Bioengineering
CJ Pharma Overseas Business/Strategic Planning
CJ America Inc. Licensing/Business Development/Investment
President, InnoTherapy USA Inc.
Scientific Advisory Board
Professor David V. Schaffer
SAB | AAV Gene Therapy
David Schaffer is a world-leading pioneer in gene and stem cell therapies, serving as the Hubbard Howe Professor of Chemical and Biomolecular Engineering, Bioengineering, and Molecular and Cell Biology at UC Berkeley. He earned his B.S. from Stanford University and a Ph.D. from MIT, followed by postdoctoral training at the Salk Institute.
His groundbreaking research utilizes directed evolution to engineer highly targeted viral vectors for advanced therapeutics. Professor Schaffer has published over 250 papers, holds more than 50 issued patents, and has successfully advanced proprietary technologies into over 10 human clinical trials. He also directs major innovation hubs at UC Berkeley, including QB3 and Bakar Labs.
As an active bio-entrepreneur, he has co-founded seven biotech companies, notably including 4D Molecular Therapeutics (NASDAQ: FDMT). His monumental contributions have earned him election to the National Academy of Engineering and the National Academy of Inventors, alongside the prestigious AIChE Acrivos Award, ACS Marvin Johnson Awards, and others.
Professor Gyun Min Lee
SAB | Bioprocess CMC
Gyun Min Lee is a world-renowned authority in biopharmaceutical manufacturing (CMC) and cell culture engineering, currently serving as the Provost and Executive Senior Vice President of KAIST. He earned his Ph.D. in Chemical Engineering from the University of Michigan, following his B.S. and M.S. degrees from Seoul National University.
As a foremost leader securing global leadership in bioprocess technologies, Professor Lee plays a pivotal role in national advisory initiatives, shaping national bio-industrial policies. His extensive administrative leadership includes serving as KAIST’s Vice President for International Relations and Dean of the College of Life Science and Bioengineering. Globally, he directed major research as a Scientific Director at the Technical University of Denmark (DTU) from 2015 to 2020.
With over 259 peer-reviewed publications, he serves as an indispensable industrial consultant and collaborator for numerous global biotechnology companies, bridging academic excellence with large-scale industrial therapeutic protein production.
Platform Leaders
Chang-Min Kang
ATLAS
Ph.D. in Molecular Biology,
Korea University
Hong-Young Choi
AIMING
Ph.D. in Physics,
Seoul National University
Kyung-Soo Kim
GRADE
Ph.D. in Biological Sciences,
KAIST